Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Egetis Therapeutics, Audiocast, Press Conference, 2025

By Inderes10/23/2025, 8:00 AM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:00 - 00:00

Please go ahead.

Nicklas Westerholm
00:04 - 05:24

Welcome to the Egetis Therapeutics webcast. My name is Nicklas Westerholm, CEO of Egetis Therapeutics. Joining me today are Christian Sonesson, Vice President of Product Strategy and Development, Yilmaz Mahshid, Chief Financial Officer, as well as Karl Hård, Head of Investor Relations. This morning, we issued a press release announcing that Egetis Therapeutics has been granted a rolling new drug application, a so-called NDA review by the US FDA for Emcitate® for the treatment of MCT8 deficiency based on currently available clinical data. This is great news and the result of a very successful pre-NDA meeting we had with the FDA earlier this week. Following the granting of the Breakthrough Therapy designation in July. We are strongly encouraged by the dialogue with the FDA on Emcitate, and we appreciate the agency's collaborative spirit as we work to deliver the first therapy to patients with MCT8 deficiency as efficiently as possible in the US. The objective of the Pre-NDA meeting was to seek FDA advice and agreement on the overall content to support our NDA submission for Emcitate, with a special focus and emphasis on the clinical data package. We have now reached an agreement with the FDA that we can commence a rolling NDA submission in December 2025, targeting a complete NDA submission in early 2026 and the completion of the FDA review process in the third quarter of 2026, as we expect a priority review. This is, of course, a substantial step towards approval in the United States. The Breakthrough Therapy designation was granted in July this year, based on the FDA's review of our independent analysis of the survival data from the international cohort study conducted by the Erasmus Medical Center, which we call the EMC Survival Study. We will start the rolling submission in December with the non-clinical and quality modules of the NDA dossier, and complete the NDA with a clinical module in early 2026. Importantly, the NDA for Emcitate® for the treatment of MCT8 deficiency will be based on currently available clinical data. Considering that MCT8 deficiency is an ultra-rare disease, we have an unusually large and robust clinical data set from six different sources. This includes Triac Trial I with 46 patients, Triac Trial II with 22 patients, where data in the NDA will include long-term safety data up to four years of treatment in younger children. The ReTRIACt study involved 15 patients, the EMC Cohort Study included 67 patients, and the EMC Survival Study comprised over 600 patients, as well as the US Expanded Access Program, where we currently have around 30 patients. Importantly, the ongoing ReTRIACt study is no longer considered pivotal for the new drug application, which it was when the study was originally designed. The study will be closed as soon as possible, and no further patients will be added. The FDA has recommended that the statistical analysis plan be revised. The so-called SAP for the trial will be revised. While I can't comment on any specific details about the ReTRIACt study or the SAP. What I can say is the revised SAP will reflect the fact that the ReTRIACt study is now a complementary study to the survival data and other clinical components in the NDA, rather than being the pivotal study. We estimate top-line results from the ReTRIACt study will be communicated during the fourth quarter of 2025. Data accrued to date will be included in the NDA. So in summary, we are very pleased with the agreement with the FDA, which provides a clear path to an NDA for Emcitate in the US, based on the currently available clinical data within the coming months. So with that, I would like to open up for questions. Operator. Please go ahead.

Operator
05:26 - 05:39

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. The next question comes from Chiara Monteroni from Van Lanschot Kempen. Please go ahead.

Chiara Monteroni
05:46 - 06:09

Hello, Tim. Congratulations on the update and thanks for taking my question. So, as Emcitate oversight has transitioned in the past from the trade division to the endocrinology division, Can you share your thoughts on how this is affecting the regulatory process? Do you believe that this new division facilitated the possibility of a rolling submission?

Nicklas Westerholm
06:11 - 07:29

The next question comes from Chiara Monteroni from Van Lanschot Kempen. Of course. And good morning, Chiara. Good to speak to you again. Now, I think it's a valid question, and as you pointed out, previously our application or IND was situated with the rare disease division. As I mentioned during my initial opening remarks, the dialogue with the FDA has been very open and positive, and we are strongly encouraged by the agency's collaborative spirit. And I think there is a strong appreciation from the agency and the Division of Endocrinology that the unmet medical need for patients with MCT8 deficiency is high, that we have generated an unusually large and robust clinical data set to date, and an appreciation of the disease itself being an ultra-orphan condition. So overall for us, that has been very positive, which was reflected in, I would say, the outcome of the Pre-NDA meeting we held earlier this week.

Chiara Monteroni
07:31 - 07:50

Yes. Really clear. And if I may, I have another question I actually wanted to ask about. Powering. But I will ask it another time. So when are we going to be able to see the survival study published by Erasmus? I know it's in their hands, but I was wondering if maybe you have some timelines.

Nicklas Westerholm
07:51 - 08:20

That's also a very good question. Rightly pointed out, it's not in our hands. The publication and manuscript related to the survival study carried out by EMC, based on data from the international consortium, will be published in the not too distant future. I don't have the insights and I can't comment any further than that, but hopefully in the not too distant future.

Chiara Monteroni
08:21 - 08:23

The next question comes from Chiara Monteroni from Van Lanschot Kempen. Thank you so much.

Nicklas Westerholm
08:24 - 08:25

Thank you, Chiara.

Operator
08:27 - 08:31

The next question comes from Oscar Lamb from Stifel. Please go ahead.

Oscar Lamb
08:33 - 08:51

Hi, Sema, congrats. First of all, regarding the positive updates. I was just wondering, in your discussions with the FDA, have you already discussed the potential label for Emcitate®? And, in particular, if the survival data will end up in the label, which obviously would be important from a pricing perspective.

Nicklas Westerholm
08:52 - 09:39

Sure. And that's a really good question. Thank you, Oscar. And of course, we have had initial discussions around the potential label, as you always do. However, as standard practice, when you are in the process, for example. Leading up to an NDA submission and subsequently a review. This will be discussed in more detail during the review process. From a company perspective, the ambition is, of course, to have as broad a label as possible, including all the possible claims based on the clinical data we have generated to date, including survival benefits.

Oscar Lamb
09:42 - 09:43

Okay. Got it. Thank you.

Nicklas Westerholm
09:43 - 09:44

Thank you.

Operator
09:48 - 09:54

There are no more questions at this time, so I hand the conference back to the speakers for written questions and closing comments.

Karl Hård
09:55 - 10:09

So we have some written questions. And the first one comes from Frederick Tower. And the question is, given that the ReTRIACt study is considered complementary, does it mean that the statistical results are a bit more flexible?

Nicklas Westerholm
10:11 - 10:39

Well, I can't comment in detail. Frederick, thank you for your written question. As mentioned in my opening remarks, while I can't comment on any specific details about the ReTRIACt study or the SAP, what I can say is the revised SAP will reflect the fact that the ReTRIACt study is now considered to be complementary to the survival data and other clinical components in the NDA, rather than a pivotal study.

Karl Hård
10:42 - 12:12

And then there is a follow-up question from Frederick Tower. You mentioned that there is a collaborative spirit at the FDA regarding the priority review voucher program and its potential end. How much does this impact the FDA's plans to make a decision before the end of September? And this is Karl Hård. I can comment on this. I mean, at the moment, the sunset clause for the PRV program is, as you said, the end of September 2026. We know from before that the FDA is forthcoming in trying to be helpful. However, it's also important to note that there is a bill in the House, number H.R. 1262, which is called Give Kids a Chance, has passed the first committee with a vote of 47 to zero to be pushed forward for a vote in the whole House. It currently has over 310 co-sponsors from both Republicans and Democrats. So, that looks very promising that it will also be going forward. If that becomes law, then it would mean that the program would be prolonged until the end of September 2029. But that still needs to happen then.

Nicklas Westerholm
12:18 - 12:55

Thank you so much, Karl, for that update. And with that, we'd like to take the opportunity to thank the participants joining the call today. In summary, we are incredibly pleased with the discussions and the agreement with the FDA, and with the clear path forward to an NDA for Emcitate® in the US, based on the currently available clinical data already in the coming couple of months. We look forward to keeping the market updated as we progress. Thank you very much, and I wish you all a good day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…